To O
determine O
the O
prevalence O
and O
characterize O
demographic O
, O
clinical O
, O
and O
genetic O
of O
familial O
Mediterranean D
fever D
( O
FMF O
) O
of O
late O
onset O
, O
all O
patients O
experiencing O
their O
first O
FMF O
attack O
at O
age O
40 O
years O
or O
more O
were O
identified O
using O
the O
computerized O
registry O
of O
our O
FMF O
clinic, O
and O
then O
thoroughly O
interviewed O
and O
examined O
. O
 
Friedreich O
ataxia O
is O
an O
autosomal O
recessive D
disorder D
caused O
by O
mutations O
in O
the O
FRDA O
gene O
that O
encodes O
a O
210 O
- O
amino O
acid O
protein O
called O
frataxin O
. O
 
A O
health O
care O
management O
system O
for O
use O
by O
hospitals O
, O
physicians O
, O
insurance O
companies O
, O
health O
maintenance O
organizations O
, O
and O
others O
in O
the O
health O
care O
field O
includes O
a O
processing O
unit O
and O
health O
condition O
guidelines O
. O
 
Motor O
incoordination O
, O
immune O
deficiencies O
, O
and O
an O
increased O
risk O
of O
cancer O
are O
the O
characteristic O
features O
of O
the O
hereditary O
disease O
ataxia O
- O
telangiectasia O
( O
A O
- O
T O
) O
, O
which O
is O
caused O
by O
mutations O
in O
the O
ATM O
gene O
. O
 
Consequently O
, O
86 O
% O
of O
afibrinogenemia O
alleles O
analyzed O
to O
date O
have O
truncating O
mutations O
of O
FGA O
, O
though O
mutations O
in O
all O
3 O
fibrinogen O
genes O
, O
FGG O
, O
FGA O
, O
and O
FGB O
, O
might O
be O
predicted O
to O
cause O
congenital D
afibrinogenemia D
. O
 
Using O
DNA O
of O
a O
patient O
with O
piebaldism O
, O
mental O
retardation O
, O
and O
multiple O
congenital D
anomalies D
associated O
with O
a O
46 O
, O
XY O
, O
del(4) O
(q12q21.1) O
karyotype O
, O
we O
carried O
out O
quantitative O
Southern O
blot O
hybridization O
analyses O
of O
the O
KIT O
gene O
and O
the O
adjacent O
PDGFRA O
( O
platelet O
- O
derived O
growth O
factor O
receptor O
alpha O
subunit O
) O
genes O
. O
 
Any O
medical O
treatment O
has O
2 O
components O
, O
the O
first O
being O
the O
specific O
effects O
of O
the O
treatment O
itself O
, O
the O
second O
, O
the O
knowledge O
that O
the O
treatment O
is O
being O
performed O
( O
the O
placebo O
effect O
) O
. O
 
We O
report O
here O
a O
newly O
identified O
HPRT O
mutation O
in O
a O
Japanese O
patient O
with O
Lesch D
- D
Nyhan D
syndrome D
. O
 
This O
could O
be O
because O
the O
68 O
Val O
- O
- O
Met O
mutation O
happened O
to O
arise O
in O
an O
A O
gene O
in O
the O
first O
instance O
, O
or O
because O
the O
68 O
Val O
- O
- O
Met O
mutation O
alone O
is O
not O
sufficient O
to O
cause O
G6PD D
deficiency D
. O
 
A O
family O
with O
inherited O
deficiency O
of O
complement O
factor O
2 O
( O
C2 O
) O
is O
described O
in O
which O
two O
family O
members O
with O
homozygous O
C2 O
deficiency O
developed O
cutaneous O
vasculitis O
and O
sicca D
syndrome D
. O
 
Since O
early O
diagnosis O
of O
even O
a O
disseminated O
fungal O
infection O
is O
difficult O
and O
treatment O
often O
ineffective O
in O
a O
patient O
with O
persistent O
granulocytopenia O
, O
we O
have O
prospectively O
evaluated O
continued O
antibiotic T
therapy T
and O
early O
empiric O
antifungal O
therapy O
in O
patients O
with O
prolonged D
fever D
and O
granulocytopenia O
. O
 
Choroideremia O
( O
CHM O
) O
is O
an O
X O
- O
linked O
progressive O
degeneration O
of O
the O
choroid O
and O
retina O
. O
 
12% O
of O
unrelated O
male O
patients O
carry O
deletions O
of O
the O
partially O
cloned O
CHM O
gene O
. O
 
The O
initiation O
and O
progression O
of O
cancer O
is O
controlled O
by O
both O
genetic O
and O
epigenetic O
events O
. O
 
Unlike O
genetic O
alterations O
, O
which O
are O
almost O
impossible O
to O
reverse O
, O
epigenetic O
aberrations O
are O
potentially O
reversible O
, O
allowing O
the O
malignant O
cell O
population O
to O
revert O
to O
a O
more O
normal O
state O
. O
 
With O
the O
advent O
of O
numerous O
drugs O
that O
target O
specific O
enzymes O
involved O
in O
the O
epigenetic O
regulation O
of O
gene O
expression O
, O
the O
utilization O
of O
epigenetic O
targets O
is O
emerging O
as O
an O
effective O
and O
valuable O
approach O
to O
chemotherapy T
as O
well O
as O
chemoprevention O
of O
cancer D
. O
 
Alzheimer O
disease O
( O
AD O
) O
is O
a O
neurodegenerative O
disorder O
characterized O
by O
cognitive O
decline O
, O
impaired O
performance O
of O
activities O
of O
daily O
living O
, O
and O
behavioral O
and O
psychiatric O
signs O
and O
symptoms O
. O
 
Memantine O
is O
a O
low O
- O
to O
moderate O
- O
affinity O
, O
uncompetitive O
N O
- O
methyl O
- O
D O
- O
aspartate O
receptor O
antagonist O
. O
 
Controlled O
trials O
have O
demonstrated O
the O
safety O
and O
efficacy O
of O
memantine T
monotherapy T
for O
patients O
with O
moderate O
to O
severe O
Alzheimer O
disease O
but O
no O
controlled O
trials O
of O
memantine O
in O
patients O
receiving O
a O
cholinesterase O
inhibitor O
have O
been O
performed O
. O
 
Golden O
retriever O
muscular O
dystrophy O
( O
GRMD O
) O
is O
a O
spontaneous O
, O
X O
- O
linked O
, O
progressively O
fatal O
disease O
of O
dogs O
and O
is O
also O
a O
homologue O
of O
Duchenne D
muscular D
dystrophy D
DMD D
. O
 
Single O
- O
drug O
therapy O
remains O
the O
preferred O
way O
to O
begin O
treatment O
of O
hypertension D
, O
although O
in O
many O
patients O
this O
is O
unable O
to O
bring O
blood O
pressure O
( O
BP O
) O
to O
goal O
levels O
. O
 
Investigated O
the O
safety O
and O
efficacy O
of O
risperidone O
( O
RPD O
) O
in O
the O
treatment O
of O
183 O
adult O
schizophrenic O
patients O
and O
determined O
the O
drug O
' O
s O
optimal O
dose O
. O
 
In O
a O
double O
- O
blind O
study O
, O
we O
compared O
the O
final O
outcome O
of O
99 O
Bell O
' O
s O
palsy O
patients O
treated O
with O
either O
acyclovir O
- O
prednisone O
( O
53 O
patients O
) O
or O
placebo O
- O
prednisone O
( O
46 O
patients O
) O
. O
 
In O
1994 O
, O
the O
National O
Center O
for O
Health O
Statistics O
estimated O
that O
more O
than O
14 O
million O
people O
( O
54 O
per O
thousand O
) O
had O
chronic O
bronchitis O
and O
sought O
treatment O
for O
90.9 O
% O
of O
their O
acute O
episodes O
. O
 
However O
, O
few O
studies O
have O
been O
done O
on O
the O
treatment O
cost O
of O
chronic O
bronchitis O
using O
national O
data O
. O
 
We O
conducted O
a O
retrospective O
analysis O
of O
claims O
for O
patients O
treated O
for O
acute D
exacerbations D
of D
chronic D
bronchitis D
( O
AECB O
) O
to O
assess O
the O
requency O
of O
services O
rendered O
and O
the O
costs O
to O
the O
health O
care O
system. O
 
Estrogen T
replacement T
therapy T
for O
1 O
year O
did O
not O
slow O
disease O
progression O
nor O
did O
it O
improve O
global, O
cognitive, O
or O
functional O
outcomes O
in O
women O
with O
mild O
to O
moderate O
Alzheimer D
Disease D
. O
 
The O
study O
does O
not O
support O
the O
role O
of O
estrogen O
for O
the O
treatment O
of O
this O
disease O
. O
 
Transplantation O
of O
insulin O
- O
producing O
cells O
offers O
a O
promising O
therapy O
to O
treat O
diabetes D
. O
 
However O
, O
due O
to O
the O
limited O
number O
of O
donor O
islet O
cells O
available O
, O
researchers O
are O
looking O
for O
different O
sources O
of O
pancreatic O
islet O
progenitor O
or O
stem O
cells O
. O
 
The O
Zaire O
subtype O
of O
Ebola T
virus T
( T
EBO-Z T
) T
is O
lethal O
for O
newborn O
mice O
, O
but O
adult O
mice O
are O
resistant O
to O
the O
virus O
, O
which O
prevents O
their O
use O
as O
an O
animal O
model O
of O
lethal O
Ebola D
infection D
. O
 
Effective O
antiviral T
agents T
are O
needed O
to O
treat O
severe D
acute D
respiratory D
syndrome D
- D
associated D
coronavirus D
( D
SARS-CoV D
) D
infection D
. O
 
The O
acne O
lesions O
characteristic O
of O
Behçet O
' O
s O
syndrome O
are O
not O
sterile O
and O
are O
commonly O
observed O
in O
combination O
with O
arthritis O
. O
 
Research O
into O
the O
pathogenesis O
of O
Behçet O
' O
s D
syndrome D
has O
shown O
that O
the O
most O
consistent O
genetic O
marker O
of O
Behçet O
' O
s O
syndrome O
is O
HLA-B51 O
; O
however O
, O
the O
genetic O
association O
of O
this O
true O
- O
to O
- O
form O
' O
complex O
' O
disorder O
with O
HLA-B51 O
is O
only O
20 O
% O
, O
and O
a O
whole O
- O
genome O
study O
showed O
associations O
with O
16 O
different O
loci O
. O
 
Since O
the O
1980s O
there O
has O
been O
a O
marked O
increase O
in O
the O
recognition O
and O
reporting O
of O
highly O
invasive O
group O
A O
streptococcal O
infections O
with O
or O
without O
necrotizing O
fasciitis O
associated O
with O
shock T
and T
organ T
failure T
. O
 
Such O
dramatic O
cases O
have O
been O
defined O
as O
streptococcal O
toxic D
- D
shock D
syndrome D
. O
 
Adherence O
to O
medical O
regimens O
for O
children O
and O
adolescents O
with O
chronic O
conditions O
is O
generally O
below O
50% O
and O
is O
considered O
the O
single O
, O
greatest O
cause O
of O
treatment O
failure O
. O
 
To O
assess O
the O
efficacy O
of O
ultrasound T
treatment T
for O
mild D
to D
moderate D
idiopathic D
carpal D
tunnel D
syndrome D
. O
 
In O
this O
preliminary O
study O
, O
a O
yoga O
- O
based O
regimen O
was O
more O
effective O
than O
wrist O
splinting O
or O
no O
treatment O
in O
relieving O
some O
symptoms O
and O
signs O
of O
carpal D
tunnel D
syndrome D
. O
 
Yoga O
and O
relaxation O
techniques O
have O
been O
used O
to O
help O
alleviate O
musculoskeletal D
symptoms D
. O
 
However O
, O
except O
for O
a O
previous O
study O
on O
osteoarthritis O
of O
the O
hand O
, O
3 O
to O
our O
knowledge O
, O
these O
methods O
have O
not O
been O
studied O
in O
a O
prospective O
controlled O
trial O
. O
 
The O
treatment O
guidelines O
for O
tuberculosis D
treatment O
under O
Directly O
Observed O
Treatment O
, O
Short O
- O
course O
( O
DOTS O
) O
have O
been O
a O
common O
strategy O
for O
TB T
treatment T
in O
Zambia D
. O
 
Tuberculosis O
is O
one O
of O
the O
major O
public O
health O
risk O
factors O
of O
high O
mortality O
among O
patients O
in O
Zambia O
. O
 
The O
prevalence O
of O
tuberculosis D
among O
adults O
has O
more O
than O
doubled O
since O
the O
onset O
of O
AIDS O
epidemic O
in O
Zambia O
[ O
1 O
] O
, O
with O
most O
of O
the O
cases O
often O
related O
to O
HIV O
/ O
AIDS O
conditions O
. O
 
Studies O
[ O
13 O
] O
have O
shown O
that O
stigmatization O
creates O
a O
lot O
of O
self O
- O
denial O
among O
those O
with O
diseases O
like O
Tuberculosis O
and O
Sexually O
Transmitted O
Infections O
( O
STIs O
) O
; O
hence O
most O
of O
them O
fail O
to O
comply O
with O
the O
treatment O
regime O
. O
 
The O
prevalence O
of O
mitral O
valve O
prolapse O
in O
patients O
with O
Down D
syndrome D
: O
implications O
for O
dental T
management T
. O
 
Asthmatic O
patients O
from O
western O
Canada O
and O
the O
United O
States O
have O
reported O
that O
after O
visits O
to O
an O
asthma O
clinic O
in O
Mexicali O
, O
Mexico O
, O
they O
return O
home O
substantially O
improved O
or O
cured O
having O
received O
" O
a O
bronchodilator O
medication O
unavailable O
in O
the O
United O
States O
or O
Canada O
because O
of O
the O
big O
drug O
companies O
. O
" O
 
It O
is O
argued O
that O
the O
proportion O
of O
fear O
, O
conviction O
, O
and O
bodily O
preoccupation O
in O
a O
given O
hypochondriacal O
patient O
may O
have O
important O
treatment O
implications O
. O
 
Studies O
are O
reviewed O
that O
have O
addressed O
psychodynamic O
and O
supportive T
psychotherapy T
, T
cognitive T
- T
behavioral T
therapy T
, T
and T
pharmacologic T
therapy T
. O
 
As O
its O
name O
suggests O
, O
this O
book O
is O
about O
psychological O
treatment O
, O
mainly O
cognitive O
behavioural O
therapy O
( O
CBT O
) O
, O
for O
hypochondriasis O
. O
 
The O
two O
authors O
are O
experienced O
clinical O
psychologists O
working O
at O
the O
Mayo O
Clinic O
. O
 
The O
emergence O
and O
spread O
of O
antibiotic D
- D
resistant D
Streptococcus D
pneumoniae D
in O
US O
communities O
is O
due O
, O
in O
part O
, O
to O
the O
excessive O
use O
of O
antibiotics T
for O
acute D
respiratory D
tract D
infections D
. O
 
To O
decrease O
total O
antibiotic O
use O
for O
uncomplicated O
acute D
bronchitis D
in O
adults O
. O
 
Four O
selected O
primary O
care O
practices O
belonging O
to O
a O
group O
- O
model O
health O
maintenance O
organization O
in O
the O
Denver O
, O
Colo O
, O
metropolitan O
area O
. O
 
A O
total O
of O
2462 O
adults O
were O
included O
at O
baseline O
and O
2027 O
adults O
were O
included O
in O
the O
study O
. O
 
Clinicians O
included O
56 O
physicians O
, O
28 O
physician O
assistants O
or O
nurse O
practitioners O
, O
and O
9 O
registered O
nurses O
. O
 
Chloromycetin O
is O
a O
crystalline O
substance O
obtained O
through O
processes O
of O
concentration O
and O
purification O
of O
cultures O
in O
liquid O
media O
of O
a O
Streptomyces O
sp. O
originally O
isolated O
by O
Burkholder O
, O
and O
shown O
by O
him O
to O
possess O
anti O
- O
bacterial O
activity O
. O
 
The O
mean O
hospital O
length O
of O
stay O
was O
6.3 O
days O
with O
a O
mean O
cost O
of O
$ O
5497 O
for O
patients O
aged O
>65 O
years O
and O
5.8 O
days O
with O
a O
mean O
cost O
of O
$ O
5561 O
for O
younger O
patients O
. O
 
We O
conducted O
a O
retrospective O
analysis O
of O
claims O
for O
patients O
treated O
for O
acute D
exacerbations D
of D
chronic D
bronchitis D
( O
AECB O
) O
to O
assess O
the O
frequency O
of O
services O
rendered O
and O
the O
costs O
to O
the O
health O
care O
system O
. O
 
A O
new O
antibiotic O
Chloromycetin O
has O
been O
clinically O
tested O
in O
the O
treatment O
of O
typhoid D
fever D
and O
has O
been O
found O
to O
exhibit O
significant O
chemotherapeutic O
effects O
. O
 
A O
description O
of O
the O
results O
in O
10 O
cases O
is O
submitted O
as O
a O
preliminary O
report O
. O
 
Follow-up O
analyses O
revealed O
4 O
regions O
of O
continued O
interest O
on O
chromosomes O
4 O
, O
6 O
, O
12 O
, O
and O
20 O
, O
with O
the O
strongest O
results O
observed O
forchromosome O
12 O
. O
 
Peak O
2-point O
affecteds-only O
lod O
scores O
( O
n=54 O
) O
were O
1.3 O
, O
1.6 O
, O
2.7 O
, O
and O
2.2 O
and O
affected O
relative O
pairs O
P O
values O
( O
n=54 O
) O
were O
.04 O
, O
.03 O
, O
.14 O
, O
and O
.04 O
for O
D12S373 O
, O
D12S1057 O
, O
D12S1042 O
, O
and O
D12S390 O
, O
respectively O
. O
 
To O
examine O
the O
effects O
of O
advance O
directives O
on O
medical O
treatments O
and O
on O
patient O
satisfaction O
and O
well-being O
and O
to O
determine O
whether O
the O
enhancement O
of O
patient O
autonomy O
through O
advance O
directives O
provides O
a O
more O
ethically O
feasible O
approach O
to O
cost O
control O
than O
does O
the O
imposition O
of O
limits O
through O
rationing O
. O
 
No O
significant O
differences O
were O
found O
between O
advance-directive O
and O
control O
groups O
regarding O
psychosocial O
variables O
, O
health O
outcome O
variables O
, O
and O
medical O
treatments O
or O
charges O
. O
 
Patients O
offered O
an O
advance O
directive O
had O
an O
average O
hospital O
stay O
of O
40.8 O
days O
( O
95 O
% O
CI, O
32.2 O
to O
49.4 O
days O
) O
, O
compared O
with O
an O
average O
of O
33.1 O
days O
( O
95 O
% O
CI O
, O
26.0 O
to O
40.2 O
days O
) O
for O
controls O
. O
 
In O
the O
development O
of O
medical O
treatments O
, O
identification O
of O
promising O
therapies O
and O
inference O
on O
selected O
treatments O
are O
usually O
performed O
in O
subsequent O
separate O
trials O
. O
 
